Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1762.94% is 38% above its 5-year average of -2845.44%, near the high end of its 5-year range (-12914.59%–-270.45%).
43.99% below its 12-month average of -1224.37%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1139.26%.
EBITDA MARGIN
-1762.94%
EBITDA MARGIN AVG TTM
-1224.37%
EBITDA MARGIN AVG 3Y
-672.24%
EBITDA MARGIN AVG 5Y
-2845.44%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-43.99%
CURRENT VS 3Y AVG
-162.25%
CURRENT VS 5Y AVG
+38.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Akanda Corp.
Market Cap
$63114.00
EBITDA Margin
-1762.94%
TTM Avg
-1224.37%
3Y Avg
-672.24%
5Y Avg
-2845.44%
Market Cap
$563178.00
EBITDA Margin
-18836.70%
TTM Avg
-9969.53%
3Y Avg
-5254.43%
5Y Avg
-4229.16%
Market Cap
$815044.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$877747.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$893920.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$897948.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akanda Corp. (AKAN) | $63114.00 | -1762.94% | -1224.37% | -672.24% | -2845.44% |
| HCW Biologics Inc. (HCWB)vs › | $563178.00 | -18836.70% | -9969.53% | -5254.43% | -4229.16% |
| CDT Equity Inc. (CDT)vs › | $693655.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $815044.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Decoy Therapeutics Inc. (DCOY)vs › | $877747.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Bone Biologics Corporation (BBLG)vs › | $897948.00 | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | -6.76% | -0.42% | 7.09% | 7.09% |
Gross Margin
-60.5%
EBITDA Margin
-1762.9%
Operating Margin
-1931.0%
Net Margin
-17690.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1139.26% |
| 2025-12-31 | -1309.48% |
| 2024-12-31 | -554.03% |
| 2024-06-30 | -471.45% |
| 2023-12-31 | -288.76% |
| 2023-06-30 | -270.45% |
| 2022-12-31 | -328.05% |
| 2022-06-30 | -12914.59% |
| 2021-12-31 | -10641.26% |
| 2021-06-30 | -537.11% |
| 2020-12-31 | -190908.39% |
| 2020-06-30 | -50000.17% |
